Key facts
- This page summarizes Jonathan Arango's Form 3 filing for MANGOCEUTICALS, INC. (MGRX).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Mar 2023, 18:23.
Jonathan Arango - 20 Mar 2023 Form 3 Insider Report for MANGOCEUTICALS, INC. (MGRX)
- Reporting relationship
- President, COO and Secretary, Director
- Issuer ticker
- MGRX
- Reported as of
- 20 Mar 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jonathan Arango
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Arango filed Form 3 for MANGOCEUTICALS, INC. (MGRX) on 20 Mar 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MGRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,000,000
- Date
- 20 Mar 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MGRX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 20 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $1.10
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
A total of 1/3 of such options vest on each of September 1, 2023, 2024 and 2025, subject to the Reporting Person's continued service with the Compan on such dates.